Associated Papers
Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment.
Nie Z et al.
Journal of Immunology (baltimore, Md. : 1950), 2018
Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
Gasparian ME et al.
Biochemistry. Biokhimiia, 2015
Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.
Bosman MC et al.
The Journal of Biological Chemistry, 2014
Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
Bychkov ML et al.
Plos One, 2014
Targeting AML through DR4 with a novel variant of rhTRAIL.
Szegezdi E et al.
Journal of Cellular and Molecular Medicine, 2011
DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.
Tur V et al.
The Journal of Biological Chemistry, 2008
Select a paper to view details